Page 6 - Ruth Reader News Today

New approaches are emerging, though some experts worry they’re uncommon and not always taken seriously in larger pandemic preparedness discussions.

Eli Lilly and Co. disclosed late Thursday that the FDA rejected its application for accelerated approval of its Alzheimer’s disease drug candidate.

CMS Administrator Chiquita Brooks-LaSure announced that the first 10 Medicare Part D drugs selected for price negotiations will be made public by Sept. 1.

A working group formed by the Center for Strategic and International Studies, a nonprofit research policy center, released a report Thursday that examines what it calls the CDC’s “moment of peril.”

The Centers for Disease Control and Prevention now reports that the Omicron variant XBB.1.5 is now the dominant SARS-CoV-2 strain in the nation.

Of course, as anyone with a pulse knows, the severity of Sam Bankman-Fried’s alleged crimes has not turned him press shy over the last two months.

And the Eurasia Group released its Top Risks of 2023 report this morning.

The spotlight is on a special election for a Virginia state Senate seat, another example of the overturning of <i>Roe</i> driving politics across the board.

The omnibus also contains a number of new FDA policies — deemed the Food and Drug Omnibus Reform Act of 2022 — that were left off the FDA User Fee Reauthorization Act of 2022 earlier this year.

Data presented this week for an Alzheimer’s drug candidate already under FDA review did little to ease doubts about its safety and efficacy.